Trial Profile

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 May 2026 According to an Everest Medicines media release, abstract has been accepted for presentation at the 63rd European Renal Association (ERA) Congress. The congress will take place in Glasgow, United Kingdom, from June 3 to 6, 2026.
04 Nov 2025 According to Calliditas Therapeutics media release, data from this trial will be presented at the 2025 American Society of Nephrology Kidney Week, taking place from November 6 to 9 in Houston, Texas.
09 Jun 2025 According to Calliditas Therapeutics media release, data from this trial presented at the 62nd European Renal Association Congress (ERA Congress)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com